🇺🇸 Eupatilin in United States

12 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pyrexia — 2 reports (16.67%)
  2. Rash — 2 reports (16.67%)
  3. Acute Hepatic Failure — 1 report (8.33%)
  4. Acute Kidney Injury — 1 report (8.33%)
  5. Adenoma Benign — 1 report (8.33%)
  6. Chest Discomfort — 1 report (8.33%)
  7. Contrast Media Reaction — 1 report (8.33%)
  8. Electrolyte Imbalance — 1 report (8.33%)
  9. Fatigue — 1 report (8.33%)
  10. Female Genital Tract Fistula — 1 report (8.33%)

Source database →

Eupatilin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Eupatilin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Eupatilin in United States?

Seoul National University Boramae Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.